Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, via della Commenda 9, 20122, Milano, Italy.
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Pediatr Nephrol. 2023 Apr;38(4):1159-1166. doi: 10.1007/s00467-022-05736-6. Epub 2022 Sep 22.
Children with underlying kidney diseases display a mild course of SARS-CoV-2 infection, but they only accounted for a minority of cases until the spread of the Omicron variant. Nonetheless, idiopathic nephrotic syndrome (INS) has been advocated as a predictor of worse outcome.
We investigated the spread, severity, and risk of relapse related to SARS-CoV-2 infection among children with INS. The incidence and characteristics of SARS-CoV-2 infections, immunosuppression, and vaccination status were retrospectively collected from the beginning of the pandemic to May 31, 2022.
We enrolled 176 patients (73 females, median age 10.22 years); 28 had a steroid-resistant disease, and 108 (61.4%) were on immunosuppressive therapy. Sixty-one (34.7%) patients reported a SARS-CoV-2 infection, with incidence peaking between December 2021 and January 2022. No hospitalization or deaths were reported, and symptoms were absent or mild. The rate of SARS-CoV-2 infection was similar in children with and without immunosuppression (33.8% vs 35.2%; p = 0.85). None of the 38 immunosuppressed patients discontinued the therapy, but they had a longer time to negativization (13.31 vs. 10.04 days; p = 0.03). Proteinuria was detected in 7 patients, but only one had a relapse requiring steroid therapy, with prompt remission and a mild course.
After the spread of the Omicron variant, the rate of SARS-CoV-2 infection in children with INS was much higher than previously reported. In this large cohort, symptoms were mild, even in immunosuppressed patients and those with proteinuria. During the infection, transient proteinuria was common with a low rate of relapses. A higher resolution version of the Graphical abstract is available as Supplementary information.
患有基础肾脏疾病的儿童感染 SARS-CoV-2 后病情较轻,但直到奥密克戎变异株传播后,此类儿童才占少数病例。然而,特发性肾病综合征(INS)已被认为是预后较差的预测指标。
我们研究了 INS 儿童中与 SARS-CoV-2 感染相关的传播、严重程度和复发风险。从大流行开始到 2022 年 5 月 31 日,我们回顾性地收集了 SARS-CoV-2 感染的发病率和特征、免疫抑制和疫苗接种情况。
我们纳入了 176 名患者(73 名女性,中位年龄 10.22 岁);28 名患者患有激素耐药性疾病,108 名(61.4%)接受免疫抑制治疗。61 名(34.7%)患者报告了 SARS-CoV-2 感染,发病率在 2021 年 12 月至 2022 年 1 月期间达到峰值。没有住院或死亡病例,症状为无症状或轻症。有免疫抑制和无免疫抑制的儿童的 SARS-CoV-2 感染率相似(33.8%与 35.2%;p=0.85)。没有 38 名免疫抑制患者停止治疗,但他们的转阴时间更长(13.31 天与 10.04 天;p=0.03)。7 名患者检测到蛋白尿,但只有 1 名需要类固醇治疗的复发,病情迅速缓解且症状较轻。
在奥密克戎变异株传播后,INS 儿童感染 SARS-CoV-2 的比例远高于之前的报告。在这个大队列中,即使是免疫抑制患者和有蛋白尿的患者,症状也较轻。在感染期间,常伴有一过性蛋白尿,复发率较低。可提供图文摘要的高分辨率版本作为补充信息。